The 25 analysts offering 12-month price forecasts for Schlumberger NV have a median target of 45.00, with a high estimate of 54.00 and a low estimate of 31.00. The median estimate represents a +5.53% increase from the last price of 42.64.
Is SLB a good stock to buy now?
The financial health and growth prospects of SLB, demonstrate its potential to outperform the market. It currently has a Growth Score of B. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B.
Will SLB stock recover?
With oil field activity recovering steadily amid the easing of curbs and oil prices rising to new highs, the sector is expected to regain the lost momentum this year. For Schlumberger Limited (NYSE: SLB), a leading provider of technology to oil and gas exploration companies, 2021 was a year of recovery.
Is Kintara Therapeutics a good buy?
Kintara Therapeutics has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Is SLB a good company?
On average, employees at Schlumberger give their company a 4.0 rating out of 5.0 – which is 3% higher than the average rating for all companies on CareerBliss. The happiest Schlumberger employees are Software Developers submitting an average rating of 4.5 and Systems Engineers also with a rating of 4.5.
Is Reeds stock a buy?
Reed’s has received a consensus rating of Buy. The company’s average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Is Ginger publicly traded?
San Francisco health startup Ginger.io went public today with a major pivot that the company has been undergoing over the last year and a half.